You are here

New Electronic Stent Could Provide Feedback and Therapy — Then Dissolve

Scientists work on next step in stent technology

Every year, an estimated half-million Americans undergo surgery to have a stent prop open a coronary artery narrowed by plaque –– but sometimes the mesh tubes get clogged.

In the journal ACS Nano, scientists have reported a new kind of multitasking stent that could minimize the risks associated with the procedure. The new stent can sense blood flow and temperature, store and transmit the information for analysis, and be absorbed by the body after it finishes its job.

Doctors have been implanting stents to unblock coronary arteries for 30 years. During that time, the devices have evolved from bare-metal mesh tubes to coated stents that can release drugs to prevent reclogging, but even these are associated with long-term re-endothelialization and inflammation, which are difficult to diagnose or treat. Researchers, therefore, have been working on designing  stents that the body can absorb to minimize the risk that a blood clot will form. Now collaborating scientists in the U.S. and Korea are taking that idea a step further.

The investigators have developed and tested in animals a drug-releasing bioabsorbable electronic stent (BES) that can provide diagnostic feedback by measuring blood flow, which slows when an artery starts narrowing. The device can also heat up on command to speed up drug delivery, and it can dissolve once it’s no longer needed.

Sources: ACS; May 27, 2015; and ACS Nano; April 23, 2015.

 

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug